SBRT for Kidney Cancer
(AQuOS-RCC Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
Stereotactic body radiotherapy (SBRT) is an emerging radiotherapy technique that precisely delivers high doses of radiation to tumours. It has been investigated as definitive treatment for an increasing variety of primary tumours including lung, liver, prostate, and now renal cell carcinoma (RCC). The principal aims of this study are to prospectively assess quality of life (QoL) and oncologic outcomes in non-surgical patients who receive SBRT for the treatment of RCC.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
Is SBRT/SABR safe for treating kidney cancer?
How is the treatment SBRT different from other treatments for kidney cancer?
SBRT (Stereotactic Body Radiation Therapy) is unique because it is a non-invasive treatment that precisely targets kidney tumors, minimizing damage to surrounding healthy tissue. It is particularly beneficial for patients who cannot undergo surgery, offering a viable alternative with promising long-term safety and efficacy.35678
What data supports the effectiveness of the treatment SBRT for kidney cancer?
Research shows that stereotactic ablative radiotherapy (SABR), which is similar to SBRT, is a promising treatment for kidney cancer, with studies indicating it is safe and effective for treating primary renal cell carcinoma. It has been shown to manage kidney cancer while preserving kidney function by reducing radiation exposure to healthy kidney tissue.357910
Are You a Good Fit for This Trial?
This trial is for adults who can't have surgery or choose not to, with kidney tumors larger than 2.5cm or recurring after treatment. They should be diagnosed with renal cell carcinoma (RCC) if possible, or show tumor growth on scans.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Radiation
Participants receive stereotactic body radiation therapy (SBRT) for the treatment of renal cell carcinoma
Follow-up
Participants are monitored for quality of life, oncologic outcomes, and treatment-related toxicity
What Are the Treatments Tested in This Trial?
Interventions
- SBRT
SBRT is already approved in United States, European Union, Canada, Japan for the following indications:
- Prostate cancer
- Lung cancer
- Liver cancer
- Pancreatic cancer
- Spinal tumors
- Prostate cancer
- Lung cancer
- Liver cancer
- Pancreatic cancer
- Spinal tumors
- Bone metastases
- Prostate cancer
- Lung cancer
- Liver cancer
- Pancreatic cancer
- Spinal tumors
- Prostate cancer
- Lung cancer
- Liver cancer
- Pancreatic cancer
Find a Clinic Near You
Who Is Running the Clinical Trial?
Sunnybrook Health Sciences Centre
Lead Sponsor
Juravinski Cancer Center
Collaborator